


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) Compounds of the formula I



in which

X denotes H or F, Cl, Br, I, CN, OCN, SCN, COR<sup>2</sup>, COOR<sup>2</sup>, CONR<sup>2</sup>R<sup>3</sup>,  
imidazolyl, pyrazolyl, triazolyl or tetrazolyl,

Y denotes -CHR<sup>2</sup>-CHR<sup>2</sup>- or -CR<sup>2</sup>=CR<sup>2</sup>-,

Q denotes O, OH, NH, NH<sup>2</sup>, NR<sup>2</sup>R<sup>3</sup>, C=O, CHOH, CHNH<sub>2</sub>, C=NH,  
CHOR<sup>2</sup> or CNR<sup>2</sup>R<sup>3</sup>,

R<sup>1</sup> denotes branched or unbranched alkylcycloalkyl, alkaryl or  
alkheteroaryl, each of which is mono- or polysubstituted by X,

R<sup>2</sup> denotes H or linear or branched alkyl or alkaryl,


R<sup>3</sup> denotes H or R<sup>2</sup>,

and


m and n, independently of one another, denote 1, 2 or 3,

and salts, solvates, racemates, enantiomers and diastereomers thereof and  
mixtures thereof in all ratios.


2. (Original) Compounds of the formula I selected from a group consisting of the  
compounds I1 to I7:







I1



I2



I3



3. (Currently Amended) Compounds of the formula I according to Claim 1 ~~or~~ 2 and physiologically acceptable salts and solvates thereof as medicaments.
4. (Currently Amended) Compounds of the formula I according to Claim 1 ~~or~~ 2 and physiologically acceptable salts and solvates thereof as medicaments having a 5-HT<sub>2A</sub> receptor-antagonistic action.
5. (Original) Medicaments according to Claim 4 for the treatment of psychoses, schizophrenia, depression, neurological disorders, memory disorders, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, eating disorders, such as bulimia, panic attacks, anorexia nervosa, sleeping disorders, such as also sleep apnoea, of premenstrual syndrome, for the prophylaxis of and for combating the consequences of cerebral infarction phenomena, such as strokes and cerebral ischaemia, and/or for positively influencing obsessive-compulsive disorder (OCD).
6. (Original) Pharmaceutical composition comprising at least one medicament according to Claim 5 and optionally excipients and/or adjuvants and optionally other active ingredients.
7. (Currently Amended) Use of compounds according to Claim 1 ~~or~~ 2 and/or of physiologically acceptable salts and solvates thereof for the preparation of a medicament having a 5-HT<sub>2A</sub> receptor-antagonistic action.
8. (Original) Use according to Claim 7 for the preparation of a medicament for the treatment of psychoses, schizophrenia, depression, neurological disorders, memory disorders, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, eating disorders, such as bulimia, panic attacks, anorexia nervosa, sleeping disorders, such as also sleep apnoea, of premenstrual syndrome, for the prophylaxis of and for combating the consequences of cerebral infarction phenomena, such as strokes and cerebral ischaemia, and/or for positively influencing obsessive-compulsive disorder (OCD).